Exemestane, an aromatase inhibitor that blocks production of estrogen, may provide another post-surgery option for postmenopausal women with hormone-receptor positive, early-stage breast cancer. In the first head-to-head adjuvant clinical trial comparing two aromatase inhibitors, anastrozole...